Christopher Blyth CC MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• June 2021

Infants aged <6 months are vulnerable to severe influenza disease and no vaccine is approved for use in this age group. We aimed to describe the epidemiology, risk factors associated with severe outcomes and management of influenza in Australian infants aged <6 months. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• December 2021

We describe contemporary antifungal use in neonates, with point-prevalence survey data from the National Antimicrobial Prescribing Survey across Australian hospitals from 2014 to 2018. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• October 2021

Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• February 2023

Australian authorities made COVID-19 vaccines available for children aged under 5 years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

Children with chronic medical conditions are at increased risk of severe influenza. Uptake of influenza vaccination in children and adolescents with these identified special risk medical conditions is suboptimal. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

Asthma exacerbations in children can be divided into IRF7hi versus IRF7lo phenotypes with associated differences in clinical phenotypes ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• March 2019

Aminoglycosides are commonly prescribed to children with febrile neutropenia (FN) but their impact on clinical outcomes is uncertain and extent of guideline compliance is unknown. We aimed to review aminoglycoside prescription and additional antibiotic prescribing, guideline compliance and outcomes for children with FN. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• September 2020

The aim of this study was to examine the prevalence of medical conditions and use of health services among young adults with Down syndrome and describe the... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• May 2014

The MECP2 mutations occurring in the severe neurological disorder Rett syndrome are predominantly de novo, with rare familial cases. The aims of this study... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• December 2012

Acute Lymphoblastic Leukemia (ALL) occurring in the first year of life is rare. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• September 2012